UK – NICE rejects NHS funding for Portola’s Ondexxya

The National Institute for Health and Care Excellence isn't recommending NHS use of Portola Pharmaceuticals' Ondexxya (andexanet alfa) for reversing the effects of anticoagulation with apixaban or rivaroxaban in adults with uncontrolled or life-threatening bleeding.

Apixaban and rivaroxaban are anticoagulants used for preventing and treating thromboembolism in conditions such as deep vein thrombosis and pulmonary embolism, but they can increase the risk of major bleeding that cannot be controlled and may be life-threatening…